Suppr超能文献

长期使用硫唑嘌呤未能预防多发性硬化症的发作:两例报告。

Long term azathioprine fails to prevent onset of multiple sclerosis: report of two cases.

作者信息

Constantinescu C S, Whiteley A, Blumhardt L D

机构信息

Division of Clinical Neurology, Queen's Medical Centre, University of Nottingham, Medical School Floor B, Nottingham NG7 2UH, UK.

出版信息

Mult Scler. 2000 Oct;6(5):362-3. doi: 10.1177/135245850000600512.

Abstract

Azathioprine is an immunosuppressive drug widely used in the treatment of chronic inflammatory diseases, including Multiple Sclerosis (MS). We report two patients who developed the first manifestations of clinically definite multiple sclerosis while on long term (3.5 and 10 years, respectively) treatment with azathioprine for Crohn's disease. Both patients developed the first MS symptoms during a quiescent phase of their inflammatory bowel disease. These cases show that long term azathioprine, while possibly maintaining inflammatory bowel disease under control, could not prevent the onset of MS. Multiple Sclerosis (2000) 6 362 - 363

摘要

硫唑嘌呤是一种免疫抑制药物,广泛用于治疗慢性炎症性疾病,包括多发性硬化症(MS)。我们报告了两名患者,他们在分别接受硫唑嘌呤长期(分别为3.5年和10年)治疗克罗恩病期间出现了临床确诊的多发性硬化症的首发症状。两名患者均在炎症性肠病的静止期出现了最初的MS症状。这些病例表明,长期使用硫唑嘌呤虽然可能使炎症性肠病得到控制,但并不能预防MS的发生。《多发性硬化症》(2000年)6卷362 - 363页

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验